Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Among 197 vaccinated people, anti-spike antibody levels fell by half between the peak at 21 to 40 days and 84 days after the second BNT162b2 dose.
“A decrease in anti-spike (S) antibody levels by a factor of two was observed from the peak (at 21 to 40 days) to 84 days after receipt of the second dose of the BNT162b2 vaccine among 197 vaccinated persons.9”
From Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616 · see citing works
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889 · see citing works
Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · doi:10.1101/2021.05.22.21257658 · Cited by 2,888 · see citing works
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674 · see citing works
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389 · see citing works
Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119 · see citing works
Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939 · see citing works
Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01449-9 · Cited by 425 · see citing works
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
Wheatley, A. K., Juno, J. A., Wang, J. J., Selva, K. J., Reynaldi, A., Tan, H.-X., Lee, W. S., Wragg, K. M., Kelly, H. G., Esterbauer, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21444-5 · Cited by 351 · see citing works
Hillus, D., Schwarz, T., Tober‐Lau, P., Vanshylla, K., Hastor, H., Thibeault, C., Jentzsch, S., Helbig, E. T., Lippert, L. J., Tscheak, P., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00357-x · Cited by 343 · see citing works
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
Ainsworth, M. A., Andersson, M. I., Auckland, K., Baillie, J. K., Barnes, E. J., Beer, S., Beveridge, A., Bibi, S., Blackwell, L., Borak, M., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30634-4 · Cited by 337 · see citing works
PRMT5 inhibition disrupts splicing and stemness in glioblastoma
Sachamitr, P., Ho, J. C., Ciamponi, F. E., Ba-Alawi, W., Coutinho, F. J., Guilhamon, P., Kushida, M. M., Cavalli, F. M. G., Lee, L., Rastegar, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21204-5 · Cited by 216 · see citing works
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Linsenmeyer, K. D., Gupta, K., & Charness, M. E. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2113090 · Cited by 157 · see citing works
Wyllie, D., Jones, H. E., Mulchandani, R., Trickey, A., Taylor-Phillips, S., Brooks, T., Charlett, A., Ades, A., EDSAB-HOME investigators, Moore, P., et al. (2020) · doi:10.1101/2020.11.02.20222778 · Cited by 96 · see citing works
Hayward, A. C., Fragaszy, E., Kovar, J., Nguyen, V., Beale, S., Byrne, T., Aryee, A., Hardelid, P., Wijlaars, L. P. M. M., Fong, W. L. E., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-048042 · Cited by 68 · see citing works
Self-citationParry, H., Tut, G., Bruton, R. K., Faustini, S. E., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K. E., Amirthalingam, G., et al. (2021) · eLife · doi:10.7554/elife.69375 · Cited by 35 · see citing works
Parry, H., Tut, G., Faustini, S. E., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K. E., Amirthalingam, G., Charlton, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3816840 · Cited by 17 · see citing works
Parry, H., Tut, G., Zuo, J., & Moss, P. A. H. (2021) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.4740080 · Cited by 12 · see citing works
Flagged first, then by citations
1 of the 22 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703 · see citing works
Antonelli, M., Penfold, R. S., Merino, J., Sudre, C. H., Molteni, E., Berry, S., Canas, L. S., Graham, M. S., Klaser, K., Modat, M., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00460-6 · Cited by 843 · see citing works
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., Dabrera, G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115481 · Cited by 807 · see citing works
Antonelli, M., Penfold, R., Merino, J., Sudre, C. H., Molteni, E., Berry, S., Canas, L., Graham, M. S., Kläser, K., Marc Modat, A., et al. (2022) · UCL Discovery (University College London) · Cited by 512 · see citing works
Zeng, G., Wu, Q., Pan, H., Li, M., Yang, J., Wang, L., Wu, Z., Jiang, D., Deng, X., Chu, K., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00681-2 · Cited by 317 · see citing works
Nordström, P., Ballin, M., & Nordström, A. (2021) · The Lancet · doi:10.1016/s0140-6736(22)00089-7 · Cited by 331 · see citing works
Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., Herzel, E., Alapi, H., Cohen, D., Muhsen, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac262 · Cited by 283 · see citing works
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., Chodick, G., Gazit, S., & Patalon, T. (2021) · Nature Communications · doi:10.1038/s41467-021-26672-3 · Cited by 261 · see citing works
COVID-19 vaccination: The road ahead
Altmann, D. M., & Boyton, R. J. (2022) · Science · doi:10.1126/science.abn1755 · Cited by 195 · see citing works
Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events
Ng, S. C., Peng, Y., Zhang, L., Mok, C. K. P., Zhao, S., Li, A., Ching, J. Y. L., Liu, Y., Yan, S., Chan, D. L. S., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326563 · Cited by 179 · see citing works
Seneff, S., Nigh, G., Kyriakopoulos, A. M., & McCullough, P. A. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113008 · Cited by 177 · see citing works
Population antibody responses following COVID-19 vaccination in 212,102 individuals
Ward, H., Whitaker, M. D., Flower, B., Tang, S. N., Atchison, C. J., Darzi, A. W., Donnelly, C. A., Cann, A., Diggle, P. J., Ashby, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28527-x · Cited by 169 · see citing works
COVID ‐19 Vaccine Response in People with Multiple Sclerosis
Tallantyre, E. C., Vickaryous, N. K., Anderson, V. M., Asardag, A. N., Baker, D., Bestwick, J. P., Bramhall, K., Chance, R., Evangelou, N., George, K., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26251 · Cited by 154 · see citing works
Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland
Rzymski, P., Poniedziałek, B., & Fal, A. (2021) · Vaccines · doi:10.3390/vaccines9111286 · Cited by 160 · see citing works
Notarte, K. I., Guerrero‐Arguero, I., Velasco, J. V., Ver, A. T., de Oliveira, M. H. S., Catahay, J. A., Khan, M. S. R., Pastrana, A. M., Juszczyk, G., Torrelles, J. B., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27688 · Cited by 143 · see citing works
Patalon, T., Gazit, S., Pitzer, V. E., Prunas, O., Warren, J. L., & Weinberger, D. M. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7382 · Cited by 141 · see citing works
Bayart, J., Douxfils, J., Gillot, C., David, C., Mullier, F., Elsen, M., Eucher, C., Eeckhoudt, S. V., Roy, T., Gérin, V., et al. (2021) · Vaccines · doi:10.3390/vaccines9101092 · Cited by 136 · see citing works
Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
Liu, Y., Zeng, Q., Deng, C., Li, M., Li, L., Liu, D., Liu, M., Ruan, X., Mei, J., Mo, R., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00373-7 · Cited by 122 · see citing works
Katikireddi, S. V., Cerqueira-Silva, T., Vasileiou, E., Robertson, C., Amele, S., Pan, J., Taylor, B., Boaventura, V., Werneck, G. L., Flores-Ortiz, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02754-9 · Cited by 124 · see citing works
Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong
Peng, Q., Zhou, R., Wang, Y., Zhao, M., Liu, N., Li, S., Huang, H., Yang, D., Au, K., Wang, H., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103904 · Cited by 119 · see citing works
COVID vaccine boosters: the most important questions
Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-02158-6 · Cited by 109 · see citing works
COVID-19 Vaccine Booster: To Boost or Not to Boost
Shekhar, R., Garg, I., Pal, S., Kottewar, S., & Sheikh, A. B. (2021) · Infectious Disease Reports · doi:10.3390/idr13040084 · Cited by 108 · see citing works
Lin, S., Kennedy, N. A., Saifuddin, A., Sandoval, D. M., Reynolds, C. J., Seoane, R. C., Kottoor, S. H., Pieper, F. P., Lin, K., Butler, D. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28517-z · Cited by 97 · see citing works
Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review
Pooley, N., Karim, S. S. A., Combadière, B., Ooi, E. E., Harris, R. C., Guerche‐Séblain, C. E., Kisomi, M., & Shaikh, N. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00753-2 · Cited by 93 · see citing works
Immune recall improves antibody durability and breadth to SARS-CoV-2 variants
Chen, Y., Tong, P., Whiteman, N. B., Moghaddam, A. S., Zarghami, M., Zuiani, A., Habibi, S., Gautam, A. K., Keerti, K., Bi, C., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp8328 · Cited by 85 · see citing works
Buhre, J. S., Pongrácz, T., Künsting, I., Lixenfeld, A. S., Wang, W., Nouta, J., Lehrian, S., Schmelter, F., Lunding, H. B., Dühring, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020844 · Cited by 87 · see citing works
Gazit, S., Saciuk, Y., Perez, G., Peretz, A., Pitzer, V. E., & Patalon, T. (2022) · BMJ · doi:10.1136/bmj-2022-071113 · Cited by 87 · see citing works
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort
Aldridge, R. W., Yavlinsky, A., Nguyen, V. G., Eyre, M. T., Shrotri, M., Navaratnam, A. M. D., Beale, S., Braithwaite, I., Byrne, T., Kovar, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32265-5 · Cited by 83 · see citing works
Self-citationCOVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly
Rzymski, P., Camargo, C. A., Fal, A., Flisiak, R., Gwenzi, W., Kelishadi, R., Leemans, A., Nieto, J. J., Ozen, A., Perc, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9111299 · Cited by 75 · see citing works
Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
Amanatidou, E., Gkiouliava, A., Pella, E., Serafidi, M., Tsilingiris, D., Vallianou, N. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100180 · Cited by 76 · see citing works
Metabolic disorders, COVID-19 and vaccine-breakthrough infections
Stefan, N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00608-9 · Cited by 71 · see citing works
Glatman-Freedman, A., Hershkovitz, Y., Kaufman, Z., Dichtiar, R., Keinan-Boker, L., & Bromberg, M. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2711.211886 · Cited by 70 · see citing works
Čalušić, M., Marčec, R., Luksa, L., Jurkovic, I., Kovač, N., Mihaljević, S., & Likić, R. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15126 · Cited by 68 · see citing works
Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers
Tober-Lau, P., Schwarz, T., Vanshylla, K., Hillus, D., Gruell, H., EICOV/COVIM Study Group, Suttorp, N., Landgraf, I., Kappert, K., Seybold, J., et al. (2021) · doi:10.1101/2021.08.26.21262468 · Cited by 69 · see citing works
Defending against SARS-CoV-2: The T cell perspective
Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 64 · see citing works
Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines
Fraser, R., Resendiz, A. O., Mazein, A., & Dockrell, D. H. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.01.003 · Cited by 61 · see citing works
Almendro-Vázquez, P., Laguna‐Goya, R., Ruiz‐Ruigómez, M., Utrero‐Rico, A., Lalueza, A., de la Calle, G. M., Delgado, P., Ordoño, L. P., Muro, E., Vila, J. J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010211 · Cited by 59 · see citing works
A Narrative Review of COVID-19 Vaccines
Eroglu, B., Nuwarda, R. F., Ramzan, I., & Kayser, V. (2021) · Vaccines · doi:10.3390/vaccines10010062 · Cited by 58 · see citing works
Bonelli, M. M., Mrak, D., Tobudic, S., Sieghart, D., Koblischke, M., Mandl, P., Kornek, B., Simader, E., Radner, H., Perkmann, T., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221558 · Cited by 59 · see citing works
Selma‐Royo, M., Bäuerl, C., Tudela, D. M., Aguilar‐Camprubí, L., Pérez-Cano, F. J., Llorca, A. P., Lerín, C., Martínez‐Costa, C., & Collado, M. C. (2022) · Genome Medicine · doi:10.1186/s13073-022-01043-9 · Cited by 59 · see citing works
Post COVID-19 condition of the Omicron variant of SARS-CoV-2
Morioka, S., Tsuzuki, S., Suzuki, M., Terada, M., Akashi, M., Osanai, Y., Kuge, C., Sanada, M., Tanaka, K., Maruki, T., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.08.007 · Cited by 59 · see citing works
Krasselt, M., Wagner, U. G., Nguyen, P., Pietsch, C., Boldt, A., Baerwald, C., Pierer, M., & Seifert, O. (2022) · Rheumatology · doi:10.1093/rheumatology/keac089 · Cited by 56 · see citing works
Cafferty, S. M., Haque, A. K. M. A., Vandierendonck, A., Weidensee, B., Plovyt, M., Stuchlíková, M., François, N., Valembois, S., Heyndríckx, L., Míchiels, J., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.04.014 · Cited by 54 · see citing works
Huang, A., Cicin‐Sain, C., Pasin, C., Epp, S., Audigé, A., Mueller, N. J., Nilsson, J., Bankova, A. K., Wolfensberger, N., Vilinovszki, O., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.01.019 · Cited by 54 · see citing works
Glatman‐Freedman, A., Bromberg, M., Dichtiar, R., Hershkovitz, Y., & Keinan‐Boker, L. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103574 · Cited by 53 · see citing works
Covid-19: virology, variants, and vaccines
Young, M., Crook, H., Scott, J. T., & Edison, P. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000040 · Cited by 52 · see citing works
Duration of immunity following full vaccination against SARS-CoV-2: a systematic review
Addo, I. Y., Dadzie, F. A., Okeke, S. R., Boadi, C., & Boadu, E. F. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00935-x · Cited by 53 · see citing works
Benning, L., Morath, C. P., Bartenschlager, M., Kim, H., Reineke, M., Beimler, J., Buylaert, M., Nußhag, C., Kälble, F., Reichel, P., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17054 · Cited by 49 · see citing works
Inequitable COVID-19 vaccine distribution and the intellectual property rights prolong the pandemic
Altındiş, E. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2014819 · Cited by 50 · see citing works
Brisotto, G., Muraro, E., Montico, M., Corso, C., Evangelista, C., Casarotto, M., Caffau, C., Vettori, R., Cozzi, M. R., Zanussi, S., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.10.035 · Cited by 47 · see citing works
Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization
Cheng, Z. J., Huang, H., Zheng, P., Xue, M., Ma, J., Zhan, Z., Gan, H., Zeng, Y., Lin, R., Li, S., et al. (2022) · Allergy · doi:10.1111/all.15271 · Cited by 49 · see citing works
Caldera, F., Knutson, K. L., Saha, S., Wald, A. M., Phan, H., Chun, K., Grimes, I. C., Lutz, M. K., Hayney, M. S., & Farraye, F. A. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001570 · Cited by 47 · see citing works
Adapting Serosurveys for the SARS-CoV-2 Vaccine Era
Duarte, N., Yanes‐Lane, M., Arora, R. K., Bobrovitz, N., Liu, M., Bego, M. G., Yan, T., Cao, C., Gurry, C., Hankins, C. A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab632 · Cited by 47 · see citing works
Sakuraba, A., Luna, A., & Micić, D. (2022) · Viruses · doi:10.3390/v14081822 · Cited by 46 · see citing works
Farroni, C., Diamanti, A. P., Aiello, A., Nicastri, E., Laganà, B., Agrati, C., Castilletti, C., Meschi, S., Colavita, F., Cuzzi, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.846753 · Cited by 45 · see citing works
Cheng, H., Peng, Z., Si, S., Alifu, X., Zhou, H., Chi, P., Zhuang, Y., Mo, M., & Yu, Y. (2022) · Vaccines · doi:10.3390/vaccines10050798 · Cited by 44 · see citing works
Anastassopoulou, C. G., Antoni, D., Manoussopoulos, Y. N., Stefanou, P., Argyropoulou, S., Vrioni, G., & Tsakris, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266958 · Cited by 42 · see citing works
Speer, C., Schaier, M., Nußhag, C., Töllner, M., Buylaert, M., Kälble, F., Reichel, P., Grenz, J., Süsal, C., Zeier, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9101130 · Cited by 42 · see citing works
Choudhary, H. R., Parai, D., Dash, G. C., Kshatri, J. S., Mishra, N., Choudhary, P. K., Pattnaik, D., Panigrahi, K., Behera, S., Sahoo, N. R., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.778129 · Cited by 42 · see citing works
Basso, P., Negro, C., Cegolon, L., & Filon, F. L. (2022) · Viruses · doi:10.3390/v14020336 · Cited by 41 · see citing works
Vadrevu, K. M., Ganneru, B., Reddy, S., Jogdand, H., Raju, D., Praturi, U., Sapkal, G. N., Yadav, P. D., Reddy, P., Verma, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16097-3 · Cited by 41 · see citing works
Amellal, H., Assaid, N., Charoute, H., Akarid, K., Maaroufi, A., Ezzikouri, S., & Sarih, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288557 · Cited by 38 · see citing works
Cheetham, N. J., Kibble, M., Wong, A., Silverwood, R. J., Knüppel, A., Williams, D. M., Hamilton, O. K., Lee, P. H., Staatz, C. B., Gessa, G. D., et al. (2023) · eLife · doi:10.7554/elife.80428 · Cited by 38 · see citing works
Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults
Erice, A., Varillas‐Delgado, D., & Caballero, C. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.08.023 · Cited by 38 · see citing works
Singh, A. K., Phatak, S., Singh, R., Bhattacharjee, K., Singh, N. K., Gupta, A., & Sharma, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102424 · Cited by 36 · see citing works
Sunagar, R., Prasad, S. D., Ella, R., & Vadrevu, K. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063679 · Cited by 38 · see citing works
Zhao, W., Chen, W., Li, J., Chen, M., Li, Q., Lv, M., Zhou, S., Bai, S., Wang, Y., Zhang, L., et al. (2022) · mBio · doi:10.1128/mbio.00181-22 · Cited by 37 · see citing works
Long-Term Analysis of Antibodies Elicited by Sputnik V in Tucuman, Argentina
Chahla, R. E., Tomas‐Grau, R. H., Cazorla, S. I., Ploper, D., Pingitore, E. V., López, M. A., Aznar, P., Alcorta, M. E., Vélez, E. M. D. M., Stagnetto, A., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100123 · Cited by 36 · see citing works
Ebinger, J. E., Joung, S. Y., Liu, Y., Wu, M., Weber, B., Claggett, B. L., Botting, P. G., Sun, N., Driver, M. P., Kao, Y. H., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059994 · Cited by 34 · see citing works
Huang, L., Li, Y., Luo, C., Chen, Y., Touil, N., Annaz, H. E., Zeng, S., Dang, T., Liang, J., Hu, W., et al. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113868 · Cited by 36 · see citing works
Sakuraba, A., Luna, A., & Micić, D. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01233-3 · Cited by 36 · see citing works
Furer, V., Eviatar, T., Freund, T., Peleg, H., Paran, D., Levartovsky, D., Kaufman, I., Broyde, A., Elalouf, O., Polachek, A., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222550 · Cited by 36 · see citing works
Marking, U. W., Havervall, S., Greilert‐Norin, N., Bladh, O., Christ, W., Gordon, M., Ng, H., Blom, K. G., Phillipson, M., Mangsbo, S. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36984-1 · Cited by 43 · see citing works
Ye, T., Zhou, J., Guo, C., Zhang, K., Wang, Y., Liu, Y., Zhou, J., Xie, Y., Li, E., Gong, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114269 · Cited by 35 · see citing works
mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship
Giannotta, G., & Giannotta, N. (2021) · Vaccines · doi:10.3390/vaccines9121503 · Cited by 32 · see citing works
Schmiedeberg, K., Vuilleumier, N., Pagano, S., Albrich, W. C., Ludewig, B., von Kempis, J., & Rubbert-Roth, A. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00328-3 · Cited by 34 · see citing works
A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants
Weinstein, J. B., Bates, T. A., Leier, H. C., McBride, S. K., Barklis, E., & Tafesse, F. (2022) · iScience · doi:10.1016/j.isci.2022.103960 · Cited by 32 · see citing works
Lechmere, T., Snell, L. B., Graham, C., Seow, J., Shalim, Z. A., Charalampous, T., Alcolea-Medina, A., Batra, R., Nebbia, G., Edgeworth, J. D., et al. (2022) · mBio · doi:10.1128/mbio.03798-21 · Cited by 30 · see citing works
Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
Jeewandara, C., Aberathna, I. S., Pushpakumara, P. D., Kamaladasa, A., Guruge, D., Wijesinghe, A., Gunasekera, B., Ramu, S. T., Kuruppu, H., Ranasinghe, T., et al. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.621 · Cited by 54 · see citing works
Sobieszczyk, M. E., Maaske, J., Falsey, A. R., Sproule, S., Robb, M. L., Frenck, R. W., Tieu, H., Mayer, K. H., Corey, L., Neuzil, K. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160565 · Cited by 33 · see citing works
Li, M., Yang, J., Wang, L., Wu, Q., Wu, Z., Zheng, W., Wang, L., Lu, W., Deng, X., Peng, C., et al. (2021) · medRxiv · doi:10.1101/2021.08.03.21261544 · Cited by 32 · see citing works
The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccinesPreprint
Liu, Y., Arase, N., Kishikawa, J.-I., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.22.457114 · Cited by 31 · see citing works
Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety
Meng, H., Mao, J., & Ye, Q. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27590 · Cited by 32 · see citing works
Wang, R., Qin, C., Du, M., Liu, Q., Tao, L., & Liu, J. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2065167 · Cited by 32 · see citing works
Effectiveness of COVID‑19 vaccines and their challenges (Review)
Marfè, G., Perna, S., & Shukla, A. K. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10843 · Cited by 31 · see citing works
Attitudes of Poles towards the COVID-19 Vaccine Booster Dose: An Online Survey in Poland
Babicki, M., & Mastalerz–Migas, A. (2022) · Vaccines · doi:10.3390/vaccines10010068 · Cited by 31 · see citing works
Ferreira, I. A. T. M., Lee, C. Y. C., Foster, W. S., Abdullahi, A., Dratva, L. M., Tuong, Z. K., Stewart, B. J., Ferdinand, J. R., Guillaume, S. M., Potts, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112991 · Cited by 28 · see citing works
Porru, S., Monaco, M. G. L., Spiteri, G., Carta, A., Pezzani, M. D., Lippi, G., Gibellini, D., Tacconelli, E., Vecchia, I. D., Sala, E., et al. (2022) · Vaccines · doi:10.3390/vaccines10081193 · Cited by 30 · see citing works
Nishimi, K. M., Neylan, T. C., Bertenthal, D., Seal, K. H., & O’Donovan, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7287 · Cited by 30 · see citing works
Baker, D., MacDougall, A. M., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103448 · Cited by 31 · see citing works
Jeewandara, C., Aberathna, I. S., Pushpakumara, P. D., Kamaladasa, A., Guruge, D., Wijesinghe, A., Gunasekera, B., Tanussiya, S., Kuruppu, H., Ranasinghe, T., et al. (2021) · medRxiv · doi:10.1101/2021.10.14.21265030 · Cited by 30 · see citing works
Syversen, S. W., Jyssum, I., Tveter, A. T., Sexton, J., Christensen, I. E., Tran, T. T., Bjørlykke, K. H., Mjaaland, S., Warren, D. J., Kvien, T. K., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002417 · Cited by 28 · see citing works
Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination
Jo, D. H., Minn, D., Lim, J., Lee, K.-D., Kang, Y. M., Choe, K. W., & Kim, K. N. (2021) · Vaccines · doi:10.3390/vaccines9101145 · Cited by 28 · see citing works
Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months
Ponticelli, D., Antonazzo, I. C., Caci, G., Vitale, A., Ragione, G. D., Romano, M. L., Borrelli, M., Schiavone, B., Polosa, R., & Ferrara, P. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab173 · Cited by 28 · see citing works
Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing
Rea, I. M., & Alexander, H. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101494 · Cited by 27 · see citing works
Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time
Havervall, S., Marking, U. W., Greilert‐Norin, N., Gordon, M., Ng, H., Christ, W., Phillipson, M., Nilsson, P., Hober, S., Blom, K. G., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1388 · Cited by 23 · see citing works
Pušnik, J., König, J., Mai, K., Richter, E., Zorn, J., Proksch, H., Schulte, B., Alter, G., & Streeck, H. (2022) · Journal of Virology · doi:10.1128/jvi.00760-22 · Cited by 27 · see citing works
Nanovaccines for Advancing Long-Lasting Immunity against Infectious Diseases
Gao, X., Wang, X., Li, S., Rahman, M. S. U., Xu, S., & Liu, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c07741 · Cited by 26 · see citing works
Rieke, G. J., van Bremen, K., Bischoff, J., ToVinh, M., Monin, M. B., Schlabe, S., Raabe, J., Kaiser, K. M., Finnemann, C., Odainic, A., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac060 · Cited by 24 · see citing works
Sikora, D., & Rzymski, P. (2022) · Vaccines · doi:10.3390/vaccines10030437 · Cited by 26 · see citing works
- Authors
- Shrotri, M., Navaratnam, A. M. D., Nguyen, V., Byrne, T., Geismar, C., Fragaszy, E., Beale, S., Fong, W. L. E., Patel, P., Kovar, J., Hayward, A. C., & Aldridge, R. W.
- Affiliations
- University College London (GB)
- Corresponding author
- Aldridge, Robert W
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 398
- Issue
- 10298
- Pages
- 385-387
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC8285117
- OpenAlex
- W3180511106
- Cited by
- 393
- References
- 22
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 34 · 2023: 93 · 2022: 175 · 2021: 73
- FWCI
- 29.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Facebook Inc
- Wellcome Trust
- MRC
- United Kingdom Department of Health and Social Care
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, ChAdOx1 nCoV-19 vaccine, COVID-19 vaccines, SARS-CoV-2 spike protein, prime-boost strategy, second vaccine dose, immunogenicity, vaccine efficacy, dosing interval
- MeSH terms
- SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, ChAdOx1 nCoV-19, Aged, Antibodies, Viral, Female, Humans, Male, Middle Aged, Time Factors, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
